NASDAQ:GILD Gilead Sciences (GILD) Stock Price, News & Analysis $166.16 -0.73 (-0.44%) As of 09:46 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Gilead Sciences Stock (NASDAQ:GILD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gilead Sciences alerts:Sign Up Key Stats Today's Range$167.68▼$167.6850-Day Range$143.72▼$174.4852-Week Range$116.88▼$176.58Volume10,909 shsAverage Volume6.82 million shsMarket Capitalization$206.10 billionP/E RatioN/ADividend Yield1.97%Price Target$170.15Consensus RatingModerate Buy Company Overview Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19. The company conducts research and sells its medicines in the United States and internationally. Gilead is led by chairman and chief executive officer Daniel O’Day, who joined the company in 2019. Through internal research and collaborations, the company continues to develop and expand treatments across its areas of focus.AI Generated. May Contain Errors. Read More Gilead Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreGILD MarketRank™: 3.98002462717 of 5 starsGilead Sciences scored higher than 80% of companies evaluated by MarketBeat, and ranked 100th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingGilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on no strong buy ratings, 23 buy ratings, 6 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Gilead Sciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageGilead Sciences has been the subject of 18 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Gilead Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Gilead Sciences are expected to grow in the coming year, from ($1.07) to $10.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Gilead Sciences is -52.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Gilead Sciences is -52.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGilead Sciences has a P/B Ratio of 9.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.64% of the float of Gilead Sciences has been sold short.Short Interest Ratio / Days to CoverGilead Sciences has a short interest ratio ("days to cover") of 3.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Gilead Sciences has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldGilead Sciences pays a meaningful dividend of 1.97%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGilead Sciences has been increasing its dividend for 10 years.Dividend SustainabilityBased on earnings estimates, Gilead Sciences will have a dividend payout ratio of 32.54% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.Read more about Gilead Sciences' dividend. News and Social Media4.1 / 5News Sentiment0.63 News SentimentGilead Sciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 57 news articles for Gilead Sciences this week, compared to 12 articles on an average week.Search Interest42 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows23 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 283% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,945,617.00 in company stock.Percentage Held by Insiders0.30% of the stock of Gilead Sciences is held by insiders.Percentage Held by Institutions83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Gilead Sciences' insider trading history. Receive GILD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GILD Stock News HeadlinesInsider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells $1,718,417.70 in Stock4 hours ago | americanbankingnews.comGilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 102,619 SharesNovember 8 at 5:45 AM | americanbankingnews.comTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.November 9 at 1:00 AM | Traders Agency (Ad)Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?November 7 at 1:03 PM | 247wallst.comGilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 9,810 SharesNovember 7 at 9:18 AM | insidertrades.comGilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?November 7 at 6:37 AM | 247wallst.comGilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O'day Sells 15,000 SharesNovember 3, 2026 | insidertrades.comGilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 3,000 Shares of Company StockOctober 17, 2026 | insidertrades.comSee More Headlines GILD Stock Analysis - Frequently Asked Questions How have GILD shares performed this year? Gilead Sciences' stock was trading at $122.74 at the beginning of the year. Since then, GILD stock has increased by 36.0% and is now trading at $166.89. How were Gilead Sciences' earnings last quarter? Gilead Sciences, Inc. (NASDAQ:GILD) posted its quarterly earnings results on Thursday, October, 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. Gilead Sciences's revenue was up 6.8% on a year-over-year basis. Read the conference call transcript. Does Gilead Sciences have any subsidiaries? Gilead Sciences subsidiaries include MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and more. Who are Gilead Sciences' major shareholders? Top institutional investors of Gilead Sciences include Robeco Institutional Asset Management B.V. (0.28%), Sumitomo Mitsui Trust Group Inc. (0.24%), Pictet Asset Management Holding SA (0.19%) and Assenagon Asset Management S.A. (0.13%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Deborah H Telman, Anthony Welters, Jeffrey Bluestone and Kelly A Kramer. View institutional ownership trends. How do I buy shares of Gilead Sciences? Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gilead Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Alibaba Group (BABA) and Intel (INTC). Company Calendar Record date for 9/29 Dividend9/15/2026Ex-Dividend for 9/29 Dividend9/15/2026Dividend Payable9/29/2026Last Earnings10/29/2026Today11/09/20268th Annual Wolfe Research Healthcare Conference11/10/20268th Annual Wolfe Research Healthcare Conference11/13/2026UBS Global Biopharma Conference 202611/17/2026Jefferies Global Healthcare Conference11/17/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Record date for 12/30 Dividend12/15/2026Ex-Dividend for 12/30 Dividend12/15/2026Dividend Payable12/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 GILD's financial health is in the Green zone, according to TradeSmith. GILD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GILD CIK882095 Webwww.gilead.com Phone(650) 574-3000Fax650-578-9264Employees17,000Year Founded1987Price Target and Rating Average Price Target for Gilead Sciences$170.15 High Price Target$200.00 Low Price Target$127.00 Potential Upside/Downside+2.0%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)($3.16) Trailing P/E RatioN/A Forward P/E Ratio16.56 P/E GrowthN/ANet Income$8.51 billion Net Margins-12.47% Pretax Margin-8.18% Return on Equity-1.85% Return on Assets-0.61% Debt Debt-to-Equity Ratio1.84 Current Ratio1.38 Quick Ratio1.22 Sales & Book Value Annual Sales$29.44 billion Price / Sales7.03 Cash Flow$10.47 per share Price / Cash Flow15.94 Book Value$18.23 per share Price / Book9.15Miscellaneous Outstanding Shares1,240,340,000Free Float1,236,618,000Market Cap$207.00 billion OptionableOptionable Beta0.35 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:GILD) was last updated on 11/9/2026 by MarketBeat.com Staff. From Our PartnersTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredOne bank just ran the numbers on gold for the next 5 yearsDeutsche Bank's research team just modeled where gold could land by 2031 if central banks keep shifting reserv...Cedar Gold Group | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHedge fund veteran reveals the ticker he's watching for Dec 9Hedge fund veteran Larry Benedict, who generated $274 million in profits for his clients, is watching one thre...Brownstone Research | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GILD Stock Alerts